ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Flyrcado is the first positron emission tomography myocardial perfusion imaging agent of its kind designed for the detection of coronary artery disease. The FDA has approved GE HealthCare’s Flyrcado ...
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...
GE HealthCare (Nasdaq: GEHC) today announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac ...
GE HealthCare’s agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado. Through their nearly 225 U.S. customers, CDL and CardioNavix ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results